Betaxolol 0.25% eye drops 0.25ml unit dose preservative free
Requires a prescription from a doctor or prescriber
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Betaxolol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Betaxolol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Betaxolol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Betaxolol on the MHRA register
Betoptic 0.25% eye drops suspension 0.25ml unit dose
Betaxolol 0.25% eye drops 0.25ml unit dose preservative free
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 6 · 1983–2026
Showing the 50 most relevant studies, sorted by most relevant.
Homayoun Zeynodini Meimand, Mousa Reza Anbarloui, Mohammad Eslamian, et al.
Neurological research, 2025
Ellen R. Strahlman
Archives of Ophthalmology, 1995
- Administration, Topical
- Carbonic Anhydrase Inhibitors
- Drug Tolerance
P. Kardas
Vascular Health and Risk Management, 2007
- Patient Compliance
- Quality of Life
- Adrenergic beta-Antagonists
Navid Elmi Sadr, E.El. Saber, Fatemeh Paknazar
Clinical and Experimental Optometry, 2021
- Lens Capsule, Crystalline
- Ocular Hypertension
- Glaucoma
David A. Plager, Jess T. Whitson, Peter A. Netland, et al.
Journal of American Association for Pediatric Ophthalmology and Strabismus, 2009
- Antihypertensive Agents
- Gels
- Glaucoma
A. Avunduk, A. Sari, N. Akyol, et al.
Ophthalmologica, 2001
- Administration, Topical
- Antihypertensive Agents
- Blood Flow Velocity
Paul Diggory, A Cassels-Brown, Andy Vail, et al.
British Journal of Ophthalmology, 1998
- Antihypertensive Agents
- Glaucoma
- Intraocular Pressure
Brian P. Ramos, Lesley A. Colgan, Eric Nou, et al.
Biological Psychiatry, 2005
- Adrenergic beta-Antagonists
- Attention
- Cognition
Ayat Allam, Mahmoud Elsabahy, Mahmoud El Badry, et al.
International Journal of Pharmaceutics, 2021
- Glaucoma
- Liposomes
- Drug Carriers
R. Schoene, T. Abuan, R. Ward, et al.
American journal of ophthalmology, 1984
- Administration, Topical
- Adrenergic beta-Antagonists
- Asthma
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
10 found
Half-life
14-22 hours
Mechanism
Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic rec…
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
89%
Half-life
14-22 hours
Protein binding
50%
Metabolism
15%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1566 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Involved in the regulation of sleep/wake behaviors PMID:31473062
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC S01ED02
ATC C07AB05
ATC S01ED52
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Betaxolol
Additional database identifiers
Drugs Product Database (DPD)
11219
ChemSpider
2279
BindingDB
50405521
Guide to Pharmacology
549
HUGO Gene Nomenclature Committee (HGNC)
HGNC:285
GenAtlas
ADRB1
GeneCards
ADRB1
GenBank Gene Database
J03019
GenBank Protein Database
178200
Guide to Pharmacology
28
UniProt Accession
ADRB1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:286
GenAtlas
ADRB2
GeneCards
ADRB2
GenBank Gene Database
Y00106
GenBank Protein Database
29371
Guide to Pharmacology
29
UniProt Accession
ADRB2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72